Pregabalin Capsule
Product Images NDC 46708-124

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 46708-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Pregabalin 100mg)

Label for Pregabalin Capsules 100 mg by Alembic Pharmaceuticals Limited. The label includes the NDC 46708-122-30, indicates the strength as 100 mg per capsule, and states the package contains 30 capsules. Storage instructions and manufacturer details in Gujarat, India are also shown, along with a barcode and pharmacist dispensing note.*

FDA Label Image

30 Capsules (Pregabalin 150mg)

Pregabalin Capsules 150 mg oral dosage form label from Alembic Pharmaceuticals Limited. The label specifies a bottle containing 30 capsules of 150 mg strength each. Includes storage instructions, pharmacist dispensing guidance, and manufacturer details in Gujarat, India. NDC 46708-123-30 is displayed along with a barcode.*

FDA Label Image

30 Capsules (Pregabalin 200mg)

Label for Pregabalin Capsules 200 mg by Alembic Pharmaceuticals Limited. The label states each capsule contains 200 mg pregabalin USP, with storage instructions at 25°C (77°F), and packaging contains 30 capsules. It includes NDC 46708-124-30, dispensing instructions for pharmacists, and barcode. Manufacturer details in Gujarat, India are also visible.*

FDA Label Image

30 Capsules (Pregabalin 225mg)

Label for Pregabalin Capsules 225 mg by Alembic Pharmaceuticals Limited. The label shows dosage form as oral capsules with a package count of 30 capsules. It includes storage instructions at 25°C with permitted excursions, prescription-only status, and manufacturer information from Gujarat, India. The NDC code 46708-125-30 and barcode are visible.*

FDA Label Image

30 Capsules (Pregabalin 25mg)

Pregabalin Capsules 25 mg oral capsules label from Alembic Pharmaceuticals Limited. The label indicates a package of 30 capsules, includes storage instructions at 25°C with permitted excursions, and states prescription use only. The NDC number 46708-119-30 is visible along with barcodes and manufacturer details.*

FDA Label Image

30 Capsules (Pregabalin 300mg)

Label for Pregabalin Capsules 300 mg by Alembic Pharmaceuticals Limited. The label states the NDC 46708-126-30 and indicates a package size of 30 capsules. Storage instructions specify 25°C with allowed excursions and dispensing in tight containers. The label notes Rx only and includes a barcode and manufacturer information.*

FDA Label Image

30 Capsules (Pregabalin 50mg)

Pregabalin Capsules 50 mg oral capsules label by Alembic Pharmaceuticals Limited. The label states storage instructions at 25°C with permitted excursions, prescribing information reference, pack size of 30 capsules, and includes an NDC number 46708-120-30. It also shows manufacturer details and a barcode.*

FDA Label Image

30 Capsules (Pregabalin 75mg)

Label for Pregabalin Capsules 75 mg by Alembic Pharmaceuticals Limited. The label shows the dosage strength (75 mg) prominently, indicates a package size of 30 capsules, and includes storage instructions at 25°C with permitted excursions. The label also features an NDC number 46708-121-30, a barcode, and notes the product is prescription-only.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula illustrating creatinine clearance (CLCr) calculation, incorporating patient age, weight, serum creatinine, and a correction factor for female patients. The formula is shown clearly as a ratio with age adjustment and gender-specific multiplier.*

FDA Label Image

Figure 10 (Pregabalin Fig10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin and placebo groups. The y-axis shows estimated percentage without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. Two lines represent Pregabalin (solid) and placebo (dashed), indicating higher survival without LTR in the Pregabalin group.*

FDA Label Image

Figure 11 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over time (from baseline to Week 12) for Pregabalin versus Placebo in a BOCF analysis. The X-axis represents the percent improvement, while the Y-axis shows the percent of subjects improved. Two lines depict Pregabalin (solid) and Placebo (dotted) with Pregabalin showing higher improvement rates.*

FDA Label Image

Figure 12 (Pregabalin Fig12)

A line graph showing the percent of subjects improved over time from baseline to Week 16 based on BOCF data for Pregabalin versus Placebo. The y-axis represents the percent of subjects improved, ranging from 0 to 100 percent, and the x-axis represents the percent improvement from baseline to Week 16. Two lines compare the outcomes, with Pregabalin shown as a solid line exhibiting higher improvement than the dotted line for Placebo.*

FDA Label Image

Figure 3 (Pregabalin Fig3)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin doses of 75 mg, 150 mg, and 300 mg taken three times a day against placebo, with separate lines for each dose and placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig4)

A line chart comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three lines, each representing a treatment group indicating varying levels of patient pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig5)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph shows improvement trends across different percentages of pain reduction, with vertical lines marking specific improvement thresholds.*

FDA Label Image

Figure 6 (Pregabalin Fig6)

A bar chart comparing responder rates (%) between different dosages of Pregabalin and placebo across two studies (E1 and E3). The x-axis shows dosage groups including placebo and varying Pregabalin doses; the y-axis shows responder rates from 0% to 60%. Study E1 includes doses from 50 mg/day to 600 mg/day, and Study E3 includes placebo and 600 mg/day doses with BID and TID regimens. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Figure 7 (Pregabalin Fig7)

A line graph depicting seizure reduction (median percentage change from baseline) versus dose in mg/day of Pregabalin from four clinical studies (E1 BID, E2 TID, E3 BID, E3 TID). The chart shows increasing seizure reduction with higher doses up to 600 mg/day, with p-values (all ≤ 0.0001 or 0.0007) indicating statistical significance at various dose points compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig9)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 450 mg, 600 mg daily, and Placebo. The graph compares the effectiveness of different Pregabalin doses and placebo across varying pain improvement percentages.*

FDA Label Image

Figure 1 (Pregabalin Figure1)

A line graph showing the percent of patients improved in pain relative to percent improvement in pain from baseline for Pregabalin capsules at 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The graph illustrates a higher percentage of patients improving with increased Pregabalin doses over placebo across the improvement scale.*

FDA Label Image

Figure 2 (Pregabalin Figure2)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph displays two curves showing greater patient improvement with Pregabalin at various pain improvement percentages.*

FDA Label Image

Structure (Pregabalin Structure)

Chemical structure of pregabalin illustrated as a 2D line formula showing its molecular framework including the amine (NH2) group and carboxylic acid (CO2H) group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.